For patients facing the deadliest forms of skin cancer, the difference between a “vaccine” and a “therapy” might seem like a semantic quibble. But in the high-stakes intersection of biotechnology and public health, that single word has become a strategic liability.
Recent clinical data suggests a potential breakthrough in oncology. A collaboration between Moderna and Merck has demonstrated that a personalized mRNA shot can halve the risk of death or recurrence in patients with high-risk melanoma after surgery. The technology is a direct evolution of the mRNA platforms that powered the global response to COVID-19, utilizing the same basic mechanism to instruct the immune system to recognize and attack specific targets.
Yet, as the science advances, the language is retreating. In its official regulatory filings and corporate communications, Moderna has largely scrubbed the word “vaccine” from its cancer program, replacing it with the more clinical “individualized neoantigen therapy,” or INT. This pivot reflects a growing tension in the medical community: the need to innovate using proven vaccine science although navigating a cultural landscape where the word “vaccine” has become politically charged.
The shift from prevention to treatment
To understand the Moderna cancer vaccine vs therapy dilemma, one must first understand the biological distinction. Traditional vaccines, like those for polio or influenza, are prophylactic; they prime the immune system to prevent an infection from taking hold. The mRNA cancer shots, however, are therapeutic. They are administered to people who already have the disease, designed to seek out and destroy remaining cancer cells to prevent the disease from returning.
Moderna’s CEO has stated that the shift to “individualized neoantigen therapy” was intended to better describe the program’s goal. By focusing on “neoantigens”—unique mutations found only in a specific patient’s tumor—the treatment is essentially a bespoke piece of software for the immune system. As a former software engineer, I recognize this as a move toward precision; the “code” is rewritten for every single patient.
Moderna is not alone in this linguistic migration. BioNTech, the German firm that co-developed the first authorized COVID-19 vaccine, has similarly shifted its terminology. Once referring to its perform as “neoantigen vaccines” around 2021, the company now utilizes the phrase “mRNA cancer immunotherapies” in its recent reporting.
Comparing Prophylactic Vaccines and Individualized Neoantigen Therapy
| Feature | Prophylactic Vaccine | Individualized Neoantigen Therapy (INT) |
|---|---|---|
| Primary Goal | Prevent initial infection | Treat existing cancer/prevent recurrence |
| Target | Common viral/bacterial proteins | Patient-specific tumor mutations |
| Customization | Mass-produced (one size fits all) | Bespoke (unique to each patient) |
| Patient Status | Healthy individuals | Patients with diagnosed cancer |
Navigating the “dirty word” of modern medicine
While the medical distinction between prevention and therapy is valid, the rebranding is likewise a response to a volatile social climate. The success of mRNA technology during the pandemic brought the platform into the spotlight, but it also linked the technology to a wave of vaccine hesitancy and political polarization in the United States.
Kyle Holen, head of Moderna’s cancer program, acknowledged this reality during a biotech event in Boston, noting that “vaccines are maybe a dirty word nowadays.” Despite this, he emphasized that the scientific community remains committed to harnessing the immune system to fight cancers the same way it fights infections.
The concern for biotech firms is practical: if a life-saving cancer treatment is labeled a “vaccine,” will patients who have grown distrustful of public health mandates refuse the treatment? In an era of heightened skepticism, the term “therapy” feels safer, more clinical, and less associated with government mandates.
The ethics of nomenclature and informed consent
Not all medical professionals agree with this strategic rebranding. Some argue that shifting the language obscures the nature of the treatment and could potentially compromise informed consent.
Ryan Sullivan, a physician at Massachusetts General Hospital who has enrolled patients in Moderna’s trials, has expressed concern over these “word games.” Sullivan has noted that there is a risk that some patients might decline a potentially life-saving treatment simply because it is labeled a vaccine. Conversely, he believes it is equally important to call the technology what it is to ensure transparency.
This creates a paradox for clinicians: they must balance the need to make a treatment accessible to a skeptical public with the ethical obligation to be precise about what that treatment is. When a patient is told they are receiving “neoantigen therapy,” they may not realize they are receiving a highly advanced form of vaccination—a distinction that could matter to their understanding of how the drug works within their body.
What this means for the future of oncology
The transition toward “immunotherapies” marks a broader shift in how we approach cancer. We are moving away from systemic poisons like traditional chemotherapy and toward “teaching” the body to heal itself. The success of the Moderna and Merck partnership in melanoma trials suggests that this personalized approach could eventually be applied to other solid tumors, including lung and pancreatic cancers.
The path forward involves navigating not just the biological hurdles of tumor evasion, but the psychological hurdles of patient trust. Whether called a vaccine or a therapy, the core innovation remains the same: using mRNA to turn the body’s own defenses into a precision weapon against malignancy.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a qualified healthcare provider regarding cancer treatments and clinical trial eligibility.
The next major milestone for these treatments will be the submission of formal regulatory filings for the melanoma program, as Moderna and Merck move toward seeking full FDA approval. We will continue to track these filings and the subsequent results of expanded clinical trials.
Do you think the terminology used by pharmaceutical companies affects your trust in new treatments? Share your thoughts in the comments below.
Keep reading
